Key result
New-onset T2DM is linked to ~2.4-fold higher serum fetuin-A, correlating with insulin resistance and CIMT.
Why the study?
The association between serum fetuin-A levels with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus was not previously established.
Are serum fetuin-A levels associated with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus?
Case-Control (n=200)
No
Are serum fetuin-A levels associated with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus?
Absolute Event Rate: 368.5% vs 152.7%
p-value: p=<0.01
Serum fetuin-A levels are significantly elevated in new-onset type 2 diabetes and correlate with insulin resistance and carotid intima-media thickness, suggesting utility as a biomarker for macroangiopathy risk.
Fetuin-A may mark IR and CIMT in new-onset T2DM; hypothesis-generating and requires prospective validation before clinical adoption.
Fetuin-A, which is known to inhibit insulin signaling and pathological calcification, has emerged as a diabetes risk biomarker. In the present study, the association between the fetuin-A levels with insulin resistance (IR) and carotid intima-media thickness (CIMT) was investigated in patients with new-onset type 2 diabetes mellitus (nT2DM). A total of 100 patients with nT2DM (nT2DM group) and 100 normal glucose tolerance (NGT group) controls were evaluated. The serum fetuin-A level was measured by a commercial solid-phase ELISA kit. The estimate of IR was calculated by homeostasis model assessment (HOMA-IR). CIMT was measured by B-mode ultrasound. The association between the serum fetuin-A levels and the metabolic parameters was also analyzed. The serum fetuin-A levels were increased significantly in the nT2DM group compared to the NGT group (368.5±15.6 mg/ml vs. 152.7±7.1 mg/ml, P<0.01). Fetuin-A was positively correlated with HOMA-IR, CIMT, glycated hemoglobin, triglyceride, low-density lipoprotein cholesterol, body mass index, systolic blood pressure, fasting blood glucose and 2 h post-glucose load blood glucose (P<0.05 and P<0.01), but negatively correlated with fasting plasma insulin, 2 h plasma insulin after glucose overload, high-density lipoprotein cholesterol and HOMA-β-cell insulin secretion index (P<0.05 and P<0.01). To the best of our knowledge, the study demonstrated for the first time that there is a significant association between the serum fetuin-A levels with IR and CIMT in nT2DM. These results indicate that serum fetuin-A levels can be used as independent markers in the diagnosis of macroangiopathies in nT2DM.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2014) conducted a case-control in New-onset type 2 diabetes mellitus (n=200). New-onset type 2 diabetes mellitus vs. Normal glucose tolerance was evaluated on Serum fetuin-A levels (p=<0.01). Patients with new-onset type 2 diabetes mellitus had significantly higher serum fetuin-A levels compared to healthy controls (368.5 vs 152.7 mg/ml), which positively correlated with insulin resistance and carotid intima-media thickness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: